Moderna announced that it is formally requesting an emergency use authorization (EUA) from the U.S. Food and Drug Administration for its messenger RNA (mRNA) vaccine candidate, while simultaneously preparing a Conditional Marketing Authorization filing with the European Medicines Agency.
The company has already entered the rolling review phase with a suite of international regulators, including the EMA, Health Canada, SwissMedic, the United Kingdom’s Medicines and Healthcare products Regulatory Agency, Israel’s Ministry of Health, and Singapore’s Health Sciences Authority. In parallel, Moderna intends to seek pre‑qualification or an emergency use listing from the World Health Organization, positioning the product for global deployment.
The FDA’s Vaccines and Related Biological Products Advisory Committee is slated to examine the vaccine’s safety and efficacy dossier, with the meeting expected to take place on Dec. 17, according to the company’s release.
Data analysis from the key Phase 3 COVE study yielded a point estimate of vaccine efficacy at 94.1%. This figure derives from a primary analysis that captured 196 confirmed COVID‑19 cases, of which 185 occurred among participants receiving placebo and 11 among those who received the vaccine.
Severe disease was observed exclusively in the placebo arm, with all 30 severe cases occurring there, and the sole death recorded to date also fell within the placebo group.
The COVE trial is a one‑to‑one, placebo‑controlled investigation enrolling more than 30,000 volunteers aged 18 and older across the United States. The enrolment strategy emphasized demographic breadth: over 7,000 participants were 65 years or older, more than 5,000 were younger than 65 yet carried high‑risk chronic conditions, and the study included upwards of 11,000 individuals from communities of color. Efficacy was reported as consistent across age, race, ethnicity, and gender categories; among the 196 cases, 33 involved older adults and 42 were reported by participants identifying with diverse communities.
Safety monitoring identified injection‑site pain, fatigue, myalgia, arthralgia, headache, and redness at the injection site as the most frequently reported adverse reactions. The incidence and intensity of these events rose after the second dose, reflecting the expected reactogenicity profile of the mRNA platform.
Related: The Villages Health settles $541.5M Medicare case
Moderna plans to submit the full data set from the Phase 3 COVE study to a peer‑reviewed journal, ensuring that the scientific community can scrutinize the findings in detail.
On the manufacturing front, the company is on schedule to produce roughly 20 million doses for distribution within the United States by the close of the calendar year. Its broader production target for 2021 ranges from 500 million to 1 billion doses worldwide, showing the scale of the effort to meet global demand.
With this filing, Moderna becomes the second organization to pursue an EUA, following Pfizer’s earlier application that cited an efficacy of 90%. AstraZeneca has disclosed an average efficacy of 70% from its own trial and is preparing a global regulatory submission, though it has not yet filed for an EUA.
The FDA has already granted emergency use authorizations for three therapeutic agents targeting COVID‑19. The antiviral remdesivir (Veklury) is approved for hospitalized patients aged 12 years and older who weigh at least 88 pounds. Eli Lilly’s neutralizing antibody bamlanivimab received authorization for non‑hospitalized adults and pediatric patients 12 years and older with confirmed infection who are at high risk of severe disease. Additionally, Regeneron’s monoclonal antibody combination of casirivimab and imdevimab is authorized for similar non‑hospitalized patients 12 years of age or older who also meet the weight threshold.
Operational plans under Operation Warp Speed indicate that vaccine distribution can commence within 24 hours of an authorization decision. Allocation will be proportional to the population of each jurisdiction and guided by CDC recommendations that prioritize high‑risk groups.
“This positive primary analysis confirms the ability of our vaccine to prevent COVID‑19 disease with 94.1% efficacy and importantly, the ability to prevent severe COVID‑19 disease,” said Stéphane Bancel, the CEO of Moderna. “We believe that our vaccine will provide a new and powerful tool that may change the course of this pandemic and help prevent severe disease, hospitalizations and death.”